Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

654 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.
Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Tokat UM, Ulukan B, Cetin M, Calisir K, Gedik ME, Bal H, Sener Sahin O, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O. Saatci O, et al. Among authors: isik a. Cell Death Dis. 2024 Jun 15;15(6):418. doi: 10.1038/s41419-024-06814-3. Cell Death Dis. 2024. PMID: 38879508 Free PMC article.
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer.
Saatci O, Kaymak A, Raza U, Ersan PG, Akbulut O, Banister CE, Sikirzhytski V, Tokat UM, Aykut G, Ansari SA, Dogan HT, Dogan M, Jandaghi P, Isik A, Gundogdu F, Kosemehmetoglu K, Dizdar O, Aksoy S, Akyol A, Uner A, Buckhaults PJ, Riazalhosseini Y, Sahin O. Saatci O, et al. Among authors: isik a. Nat Commun. 2020 May 15;11(1):2416. doi: 10.1038/s41467-020-16199-4. Nat Commun. 2020. PMID: 32415208 Free PMC article.
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.
Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Cetin M, Tokat UM, Gedik ME, Bal H, Sahin OS, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O. Saatci O, et al. Among authors: isik a. bioRxiv [Preprint]. 2023 Nov 5:2023.11.05.565697. doi: 10.1101/2023.11.05.565697. bioRxiv. 2023. Update in: Cell Death Dis. 2024 Jun 15;15(6):418. doi: 10.1038/s41419-024-06814-3 PMID: 38496603 Free PMC article. Updated. Preprint.
A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate.
Akbulut O, Lengerli D, Saatci O, Duman E, Seker UOS, Isik A, Akyol A, Caliskan B, Banoglu E, Sahin O. Akbulut O, et al. Among authors: isik a. Mol Cancer Ther. 2020 Jun;19(6):1243-1254. doi: 10.1158/1535-7163.MCT-19-0957. Epub 2020 Mar 26. Mol Cancer Ther. 2020. PMID: 32217742
654 results